Pipeline
← 실적 발표
01
02
03
04 05 06
톤
A1 A2 A3
INCY
FY2026 Q1
개선
Incyte Corporation 실적 발표
Buzzberg 분석
Povacitinib Phase III trials met primary endpoint in vitiligo
Incyte delivers a strong Q1 2026 with 20% net sales growth, driven by the core business ex-Jakafi which grew 63%. Management emphasized multiple regulatory and clinical catalysts ahead, including a potential launch of Povorcitinib for HS, Monjuvi in 1L DLBCL, and the start of pivotal trials for 734 and 989. Q1 2026 total revenue was $1.27B (+21% YoY), with total net sales of $1.1B (+20%). Jakafi sales were $758M (+7%), while core ex-Jakafi grew 63% to $342M.
Buzzberg 분석 Povacitinib Phase III trials met primary endpoint in vitiligo Incyte delivers a strong Q1 2026 with 20% net sales growth, driven by the core business ex-Jakafi which grew 63%. Management emphasized multiple regulatory and clinical catalysts ahead, including a potential launch of Povorcitinib for HS, Monjuvi in 1L DLBCL, and the start of pivotal trials for 734 and 989. Q1 2026 total revenue was $1.27B (+21% YoY), with total net sales of $1.1B (+20%). Jakafi sales were $758M (+7%), while core ex-Jakafi grew 63% to $342M. 전체 분석 보기분석 접기
Incyte delivers a strong Q1 2026 with 20% net sales growth, driven by the core business ex-Jakafi which grew 63%. Management emphasized multiple regulatory and clinical catalysts ahead, including a potential launch of Povorcitinib for HS, Monjuvi in 1L DLBCL, and the start of pivotal trials for 734 and 989. Q1 2026 total revenue was $1.27B (+21% YoY), with total net sales of $1.1B (+20%). Jakafi sales were $758M (+7%), while core ex-Jakafi grew 63% to $342M.
- NDA for Povorcitinib in HS accepted by FDA; positive Phase III results announced in vitiligo. Both support a major pipeline inflection point for the dermatology franchise.
- Ph3 trial for 989 in ET initiated with a flexible dose design; EHA update expected with ~100 ET patients and ~45+ MF patients.
- Ph3 trial for 734 (KRAS G12D inhibitor) in 1L pancreatic cancer has initiated.
매출$1.2727B-16% 전분기 대비
주당순이익(EPS)$1.81+1% 전분기 대비
영업이익률25.47%보고값
잉여현금흐름$0.3592B-31% 전분기 대비
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Regulatory
FDA accepted povacitinib NDA for hidradenitis suppurativa ahead of schedule
Guidance
Jackify XR expected to achieve 10-30% of Jackify business by 2029
핵심 내용 3개 더 보기
Guidance
Core business ex-Jackify expected to approach $3-4 billion by 2030
Pipeline
KRAS G12D inhibitor 734 entering Phase III in first-line PDAC
Pipeline
989 ET Phase III trial on track for mid-year initiation
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $1.2727B | -16% 전분기 대비 |
| 주당순이익(EPS) | $1.81 | +1% 전분기 대비 |
| 영업이익률 | 25.47% | 보고값 |
| 잉여현금흐름 | $0.3592B | -31% 전분기 대비 |
| 자본지출 | $0.0102B | 보고값 |
| 순이익 | $0.3033B | +1% 전분기 대비 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 매출 | FY2026 | $4.77B–$4.94B | $4.855B | 유지 |
| 매출JAKAFI | FY2026 | $3.22B–$3.27B | $3.245B | 유지 |
| 매출OPZELURA | FY2026 | $0.75B–$0.79B | $0.77B | 유지 |
| 매출HEMONC | FY2026 | $0.8B–$0.88B | $0.84B | 유지 |
AI, 자본지출 및 수요 분석
경영진 분석
Upbeat
Management highlighted strong sales growth, multiple regulatory milestones, and a confident outlook on pipeline catalysts, reflecting a positive and forward-looking tone.
외부 신호
공급망 알파 · 3발표 이후 수익률
Incyte believes that the approval of oral treatments for vitiligo will 'medicalize' the condition, expanding the overall market significantly. This is a key strategic bet that the category will grow beyond current treatment rates, driven by awareness and new oral options.
근거
“these approvals will create awareness that vitiligo is a chronic inflammatory disorder. And I think that is important for everybody that's going to be in the vitiligo market. This is definitely about medicalizing the condition.”
The KRAS G12D inhibitor (734) combination with chemotherapy is being positioned as a potential standard-of-care shift in first-line pancreatic cancer. Incyte highlights the manageable tolerability without compromising chemo dose intensity as a key differentiator, with more data expected in H2 2026.
근거
“Given how PDAC is treated in practice, especially in the first-line setting, that ability to combine effectively with both full-dose chemotherapy regimens is critical.”
The Phase 3 trial for 989 in ET includes a flexible dose escalation, starting at 750mg IV every two weeks with an option to increase to 2500mg based on early platelet response. This design is intended to address the heterogeneity in response and provides a template for upcoming MF trials.
근거
“The trial will utilize a flexible dosing schedule, starting with 750 mg IV every two weeks, with a single dose escalation option built in... based on early platelet response.”
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 0개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.